Institutional members access full text with Ovid®

Share this article on:

OCRIPLASMIN FOR VITREOMACULAR TRACTION: LOOKING OUTSIDE THE MACULAA Wide-Field Optical Coherence Tomography Study

Cereda, Matteo, G., MD; Preziosa, Chiara, MD; D'Agostino, Isabella, MD; Cozzi, Mariano, BSc; Bottoni, Ferdinando, MD, FEBO; Pellegrini, Marco, MD; Giani, Andrea, MD; Staurenghi, Giovanni, MD, FARVO

doi: 10.1097/IAE.0000000000001785
Original Study: PDF Only

Purpose: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer retinal layers outside the macula after intravitreal ocriplasmin injection. To study the relation between vitreous detachment and attenuation of retinal outer segments signal.

Methods: Retrospective cases series of 15 eyes. Each eye was scanned with the 55° wide-field optical coherence tomography lens in 6 different locations, three horizontal B-scan (central, temporal, and nasal) and three vertical B-scan (central, superior, and inferior) at baseline, 1 week, 1 month, 3 months, and 6 months after injection.

Results: After ocriplasmin injection, vitreomacular traction (VMT) resolved in 12 patients (80%), 3 of them presenting a complete posterior vitreous detachment. Eight patients (53%) showed a panretinal attenuation of photoreceptors outer segment signal, 7 with VMT resolution and 1 with non-posterior vitreous detachment and no VMT resolution. In three patients after VMT resolution the attenuation involved also areas with no posterior vitreous detachment. The attenuation resolved during follow-up in 7/8 eyes (87.5%).

Conclusion: Intravitreal ocriplasmin injection induced resolution of VMT in most cases and more rarely a release of vitreopapillary adhesion and a complete posterior vitreous detachment. An acute panretinopathy was visible in more than half of the patients and was not related to vitreous detachment.

Fifteen patients treated with intravitreal ocriplasmin were studied with the 55° wide-field OCT. Treatment induced resolution of vitreomacular traction in most cases and more rarely a complete posterior vitreous detachment. An acute panretinopathy was visible in more than half of the patients and was not related to vitreous detachment.

Eye Clinic, Department of Biomedical and Clinical Sciences “Luigi Sacco,” Luigi Sacco Hospital, University of Milan, Milan, Italy.

Reprint requests: Chiara Preziosa, MD, via G.B. Grassi 74, Milan, 20157 Italy. Eye Clinic, Department of Biomedical and Clinical Sciences “Luigi Sacco”, Luigi Sacco Hospital, University of Milan, Milan, Italy. Email: preziosachiara@gmail.com

M. G. Cereda: Consultant for Bayer (Leverkusen, Germany). M. Cozzi: financial support from Alcon (Forth Worth, TX), Bayer (Leverkusen, Germany) and Heidelberg Engineering (Heidelberg, Germany). F. Bottoni: Board membership of Bayer (Leverkusen, Germany) and Novartis (Basel, Switzerland). Payment for lectures from Alcon (Forth Worth, TX). M. Pellegrini: Board membership of Bayer (Leverkusen, Germany), Payment for lectures from Optovue Inc (Fremont, CA). A. Giani: Consultant for Bayer (Leverkusen, Germany), Novartis (Basel, Switzerland). Member of advisory board of Allergan (Parsippany-Troy Hills, NJ). G. Staurenghi: Consultant for Heidelberg Engineering (Heidelberg, Germany), Quantel Medical (Cournon-d'Auvergne, France), Carl Zeiss Meditec (Jena, Germany), Alcon (Forth Worth, TX), Allergan (Parsippany-Troy Hills, NJ), Bayer (Leverkusen, Germany), Boheringer (Ingelheim am Rhein, Germany), Genentech (San Francisco, CA), GSK (London, United Kingdom), Novartis (Basel, Switzerland), and Roche (Basel, Switzerland). Royalty from Ocular Instruments (Bellevue, WA). Grant support from Optos (Dunfermline, United Kingdom) and Centervue (Padova, Italy). The remaining authors have no any financial/conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.